Rockland Immunochemicals Inc. actively participates in the Small Business Innovation Research (SBIR) program which is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development that has the potential for commercialization. Rockland has achieved significant breakthroughs through the competitive SBIR award process to develop technologies that are ultimately made available to the research community.
Rockland successfully leverages the technical expertise of its staff by collaborating with principal investigators at academic and research facilities throughout North America, Europe and Japan including, but not limited to, Scripps Institute, Memorial Sloan-Kettering Cancer Center, Fox Chase Cancer Center, the Wistar Institute, UNC Lineberger Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, St. Jude's Children's Research Hospital, and Children’s Hospital of Philadelphia. Several R&D projects at Rockland Immunochemicals are in collaboration with agencies of the National Institutes of Health (NIH). With the National Cancer Institute we have developed novel antibody reagents and antibody-based assays for newly identified protein targets critical for the cancer research.
Rockland is successful in the competitive peer-reviewed process to receive SBIR grants and awards from the NIH. Funding allows Rockland Immunochemicals to develop innovative and cutting-edged research tools for the biomedical research community. These prestigious awards reaffirm our innovation and commitment to research and biotechnology. Below is a partial list of recent grants and awards successfully funded through the SBIR process. Click on the grant title for more information.
Rockland Immunochemicals Inc.Limerick, PA 19468E-mail: firstname.lastname@example.orgPhone: 800.656.7625